Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review - PubMed (original) (raw)
Review
. 2001 Nov 14;286(18):2270-9.
doi: 10.1001/jama.286.18.2270.
Affiliations
- PMID: 11710893
- DOI: 10.1001/jama.286.18.2270
Review
Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review
K A Phillips et al. JAMA. 2001.
Abstract
Context: Adverse drug reactions are a significant cause of morbidity and mortality. Although many adverse drug reactions are considered nonpreventable, recent developments suggest these reactions may be avoided through individualization of drug therapies based on genetic information, an application known as pharmacogenomics.
Objective: To evaluate the potential role of pharmacogenomics in reducing the incidence of adverse drug reactions.
Data sources: MEDLINE English-language only searches for adverse drug reaction studies published between January 1995 and June 2000 and review articles of variant alleles of drug-metabolizing enzymes published between January 1997 and August 2000. We also used online resources, texts, and expert opinion.
Study selection: Detailed inclusion criteria were used to select studies. We included 18 of 333 adverse drug reaction studies and 22 of 61 variant allele review articles.
Data extraction: All the investigators reviewed and coded articles using standardized abstracting forms.
Data synthesis: We identified 27 drugs frequently cited in adverse drug reaction studies. Among these drugs, 59% are metabolized by at least 1 enzyme with a variant allele known to cause poor metabolism. Conversely, only 7% to 22% of randomly selected drugs are known to be metabolized by enzymes with this genetic variability (range, P =.006-P<.001).
Conclusions: Our results suggest that drug therapy based on individuals' genetic makeups may result in a clinically important reduction in adverse outcomes. Our findings serve as a foundation for further research on how pharmacogenomics can reduce the incidence of adverse reactions and on the resulting clinical, societal, and economic implications.
Similar articles
- Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
Kirchheiner J, Seeringer A. Kirchheiner J, et al. Biochim Biophys Acta. 2007 Mar;1770(3):489-94. doi: 10.1016/j.bbagen.2006.09.019. Epub 2006 Oct 4. Biochim Biophys Acta. 2007. PMID: 17113714 Review. - The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
Lynch T, Price A. Lynch T, et al. Am Fam Physician. 2007 Aug 1;76(3):391-6. Am Fam Physician. 2007. PMID: 17708140 Review. - [Therapeutic implications of polymorphisms in cytochromes and drug transporters].
Münster E, Ziegler S, Brunner M. Münster E, et al. Wien Med Wochenschr. 2005 Feb;155(3-4):54-8. doi: 10.1007/s10354-004-0144-2. Wien Med Wochenschr. 2005. PMID: 15791777 German. - Pharmacogenetics of the cytochromes P450.
Daly AK. Daly AK. Curr Top Med Chem. 2004;4(16):1733-44. doi: 10.2174/1568026043387070. Curr Top Med Chem. 2004. PMID: 15579105 Review. - Dosing recommendations for pharmacogenetic interactions related to drug metabolism.
Filipski KK, Pacanowski MA, Ramamoorthy A, Feero WG, Freedman AN. Filipski KK, et al. Pharmacogenet Genomics. 2016 Jul;26(7):334-9. doi: 10.1097/FPC.0000000000000220. Pharmacogenet Genomics. 2016. PMID: 27058883
Cited by
- CYP2D6 isoenzyme and ABCB1 gene polymorphisms associated with postoperative nausea and vomiting in women undergoing laparoscopic cholecystectomy: a randomized trial.
Ribeiro AHS, Braga ELC, Ferreira NAG, Olej B, Verçosa N, Antunes LDS, Cavalcanti IL. Ribeiro AHS, et al. Braz J Anesthesiol. 2024 May-Jun;74(3):744423. doi: 10.1016/j.bjane.2023.02.002. Epub 2023 Feb 23. Braz J Anesthesiol. 2024. PMID: 36841429 Free PMC article. Clinical Trial. - Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.
Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, Giacomini KM, Krauss RM. Wilke RA, et al. Nat Rev Drug Discov. 2007 Nov;6(11):904-16. doi: 10.1038/nrd2423. Nat Rev Drug Discov. 2007. PMID: 17971785 Free PMC article. Review. - Clinical pharmacology: special safety considerations in drug development and pharmacovigilance.
Atuah KN, Hughes D, Pirmohamed M. Atuah KN, et al. Drug Saf. 2004;27(8):535-54. doi: 10.2165/00002018-200427080-00006. Drug Saf. 2004. PMID: 15154826 Review. - Development of the pharmacogenomics and genomics literacy framework for pharmacists.
Rahma AT, Elbarazi I, Ali BR, Patrinos GP, Ahmed LA, Elsheik M, Al-Maskari F. Rahma AT, et al. Hum Genomics. 2021 Oct 16;15(1):62. doi: 10.1186/s40246-021-00361-0. Hum Genomics. 2021. PMID: 34656176 Free PMC article. - Description of an Innovative Pediatric Individualized Therapeutics Clinic: Working toward Precision Drug Therapy.
Sandritter TL, Dinh JC, Wagner JA, Lowry JA. Sandritter TL, et al. Children (Basel). 2019 Feb 25;6(2):35. doi: 10.3390/children6020035. Children (Basel). 2019. PMID: 30823616 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical